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favour of first-line irinotecan-based therapy (Douillard et al, 2000;
Saltz et al, 2000).
We only referred to the MRC CRO8 (FOCUS) study since the
NICE panel recommended entering patients into this trial and were
planning to review their guidance when the results from this study
are available. We never questioned the ethical validity of the
FOCUS study. We simply pointed out that NICE seem to have
linked their guidance very closely to this study and feel that they
have frankly misinterpreted the many positive studies from here
and abroad. NICE also failed to appreciate that patients who were
randomised into the two oxaliplatin arms were unable to receive
irinotecan at any point, even though they supported second-line
use of this drug. We were not questioning the FOCUS study; we
simply alluded to this disparity created by NICE. Since our
editorial was published, the FOCUS study has, in our opinion,
quite rightly added a third-tier of treatment, so allowing all
patients to receive both oxaliplatin and irinotecan at some point.
However, according to NICE recommendations, patients who
prefer not to be entered into this study should only receive 5-
Fluorouracil and folinic acid (5FU/FA) ‘up-front’, unless they fall
into the very small group of patients that have potentially operable
liver metastases.
With the widespread availability of the internet and because we
need to provide enough information to allow patients to give
informed consent, they are quite rightly questioning the NICE
guidance in a similar manner to the 28 colorectal oncologists who
wrote to the Daily Telegraph in June. Patients are also rightly
concerned that the NICE guidance was influenced too much by
government funding constraints rather than clinical-effectiveness.
We would strongly urge NICE to consider a fresh review before
2005, based on both the convincing existing data (Douillard et al,
2000; Saltz et al, 2000) and the rapidly emerging new data using all
three drugs – planned or unplanned (Tournigand et al, 2001;
Goldberg et al, 2002).
REFERENCES
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P,
Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P
(2000) Irinotecan combined with fluorouracil compared with fluorour-
acil alone as first-line treatment for metastatic colorectal cancer: a
multicentre randomised trial. Lancet 355: 1041–1047
Goldberg RM, Morton RF, Sargent DJ, Fuchs C, Ramanathan RK,
Williamson S, Findlay B (2002) Oxaliplatin or CPT11+5-fluorouracil/
leucovorin or Oxa+CPT11 in advanced colorectal cancer (ACRC).
Efficacy and safety results from a North American Gastrointestinal
Intergroup Study (N9741). Abstract 6, Perspectives in Colorectal Cancer,
A consensus meeting, Fourth International Conference, Barcelona, 2002
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun
JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL (2000)
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal
cancer. Irinotecan Study Group [see comments]. N Engl J Med 343: 905–
914
Tournigand C, Louvet C, Quinaux E, Andre T, Lledo G, Flesch M, Ganem G,
Landi B, Colin P, Denet C, Mery-Mignard D, Risse M, Buyse M,
de Gramont A (2001) FOLFIRI followed by FOLFOX versus FOLFOX
followed by FOLFIRI in metastatic colorectal cancer (MCRC):
final results of a phase III study. Proc Am J Clin Oncol 20: 124a (abstract
494)
Reply 2: NICE guidelines on drugs for colorectal cancer
PJ Ross
1,2 and D Cunningham*
,1,2
1Royal Marsden Hospital, London, UK;
2Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
British Journal of Cancer (2003) 88, 1154–1155. doi:10.1038/sj.bjc.6600853 www.bjcancer.com
& 2003 Cancer Research UK
               
Sir,
Drs Mason, Johnson and Rudd suggest that criticism of the
guidance issued by the National Institute for Clinical Excellence
(NICE) regarding the use of irinotecan and oxaliplatin in the
treatment of patients with advanced colorectal cancer may have
implications for the FOCUS trial (Cunningham et al, 2002; Mason
et al, 2002; NICE, 2002; Saunders and Valle, 2002). However, the
reason for criticism of the NICE guidance is due to the
overwhelming evidence that access to the three drugs 5-
fluorouracil, irinotecan and oxaliplatin is the optimal therapeutic
approach to metastatic colorectal cancer. Subsequent to this
guidance entry into the revised FOCUS protocol is the only way
that patients in the UK can access all these agents. Therefore,
patients not participating in the FOCUS trial will receive
suboptimal therapy. Although the median survival for FOCUS
of 16 months is encouraging, and certainly a major step forward
over CRO6 with a median survival of approximately 10 months
(Maughan et al, 2002), it remains significantly less than that
for patients treated with all three agents in randomised trials such
as N9741 (Goldberg et al, 2002) and the Tournigand trial
(Tournigand et al, 2001) with median survivals of 18.6 months
(data presented at the American Society of Clinical Oncology,
Orlando, 2002) and approximately 21 months (data presented
at the American Society of Clinical Oncology, San Francisco,
2001).
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sequence of use of these three agents (combinations vs mono-
therapy), the crucial point is that all patients should have access to
these three drugs.
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